Patents by Inventor Cyril LENOUEN

Cyril LENOUEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
    Patent number: 11390651
    Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: July 19, 2022
    Assignees: The USA, Secretary, DHHS, Codagenix, Inc.
    Inventors: Cyril Lenouen, Ursula J. Buchholz, Peter L. Collins, Steffen Mueller
  • VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES
    Publication number: 20210188920
    Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Application
    Filed: August 31, 2020
    Publication date: June 24, 2021
    Inventors: Cyril LENOUEN, Ursula J. BUCHHOLZ, Peter L. COLLINS, Steffen MUELLER
  • Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
    Patent number: 10808012
    Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: October 20, 2020
    Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services, Codagenix, Inc.
    Inventors: Cyril Lenouen, Ursula J. Buchholz, Peter L. Collins, Steffen Mueller
  • VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES
    Publication number: 20190233476
    Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Application
    Filed: September 22, 2017
    Publication date: August 1, 2019
    Inventors: Cyril LENOUEN, Ursula J. BUCHHOLZ, Peter L. COLLINS, Steffen MUELLER